Hospital Acquired Pneumonia (HAP) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Hospital Acquired Pneumonia (HAP) – Pipeline Review, H1 2018’, provides an overview of the Hospital Acquired Pneumonia (HAP) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP)

– The report reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Hospital Acquired Pneumonia (HAP) therapeutics and enlists all their major and minor projects

– The report assesses Hospital Acquired Pneumonia (HAP) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hospital Acquired Pneumonia (HAP)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adenium Biotech ApS

Aridis Pharmaceuticals LLC

AstraZeneca Plc

Cardeas Pharma Corp

Centauri Therapeutics Ltd

CytaCoat AB

Destiny Pharma Ltd

Dong-A Socio Holdings Co Ltd

Lakewood-Amedex Inc

MedImmune LLC

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Merck & Co Inc

Motif Bio Plc

Nabriva Therapeutics plc

Polyphor Ltd

Sealife PHARMA GMBH

Shionogi & Co Ltd

Tetraphase Pharmaceuticals Inc

Theravance Biopharma Inc

Wockhardt Ltd

Zavante Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Hospital Acquired Pneumonia (HAP) Overview 6

Hospital Acquired Pneumonia (HAP) Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Products under Development by Companies 11

Hospital Acquired Pneumonia (HAP) Therapeutics Assessment 15

Assessment by Target 15

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Hospital Acquired Pneumonia (HAP) Companies Involved in Therapeutics Development 23

Adenium Biotech ApS 23

Aridis Pharmaceuticals LLC 23

AstraZeneca Plc 24

Cardeas Pharma Corp 24

Centauri Therapeutics Ltd 24

CytaCoat AB 25

Destiny Pharma Ltd 25

Dong-A Socio Holdings Co Ltd 26

Lakewood-Amedex Inc 26

MedImmune LLC 27

Meiji Seika Pharma Co Ltd 27

Melinta Therapeutics Inc 27

Merck & Co Inc 28

Motif Bio Plc 29

Nabriva Therapeutics plc 29

Polyphor Ltd 29

Sealife PHARMA GMBH 30

Shionogi & Co Ltd 30

Tetraphase Pharmaceuticals Inc 31

Theravance Biopharma Inc 31

Wockhardt Ltd 32

Zavante Therapeutics Inc 32

Hospital Acquired Pneumonia (HAP) Drug Profiles 34

(avibactam + ceftazidime) Drug Profile 34

(cefepime + zidebactam) Drug Profile 39

(ceftolozane sulfate + tazobactam sodium) Drug Profile 40

(cilastatin sodium + imipenem + relebactam) Drug Profile 46

(meropenem + vaborbactam) Drug Profile 48

AA-139 Drug Profile 55

Aerucin Drug Profile 56

alalevonadifloxacin Drug Profile 58

amikacin sulfate + fosfomycin Drug Profile 60

AR-401 Drug Profile 62

arbekacin Drug Profile 63

ASN-100 Drug Profile 64

cefiderocol sulfate tosylate Drug Profile 67

EBX-004 Drug Profile 72

eravacycline Drug Profile 73

exeporfinium chloride Drug Profile 82

fosfomycin tromethamine Drug Profile 85

iclaprim Drug Profile 89

lefamulin acetate Drug Profile 96

levonadifloxacin Drug Profile 102

MEDI-3902 Drug Profile 103

Mul-1867 Drug Profile 104

murepavadin Drug Profile 106

Nu-2 Drug Profile 109

Nu-3 Drug Profile 110

Panaecin Drug Profile 112

panobacumab Drug Profile 113

POL-7001 Drug Profile 115

Polysaccharides for Hospital Acquired Pneumonia Drug Profile 116

Qn-2251 Drug Profile 117

SLP-0905 Drug Profile 118

Small Molecules for Bacterial Infections, Ventilator Associated Pneumonia, Sepsis and Surgical Wound Infections Drug Profile 119

sodium hypochlorite Drug Profile 120

suvratoxumab Drug Profile 121

tedizolid phosphate Drug Profile 122

telavancin hydrochloride Drug Profile 130

tosatoxumab Drug Profile 136

Hospital Acquired Pneumonia (HAP) Dormant Projects 138

Hospital Acquired Pneumonia (HAP) Discontinued Products 139

Hospital Acquired Pneumonia (HAP) Product Development Milestones 140

Featured News & Press Releases 140

Appendix 151

Methodology 151

Coverage 151

Secondary Research 151

Primary Research 151

Expert Panel Validation 151

Contact Us 151

Disclaimer 152

List of Tables

List of Tables

Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Hospital Acquired Pneumonia (HAP) Pipeline by Adenium Biotech ApS, H1 2018

Hospital Acquired Pneumonia (HAP) Pipeline by Aridis Pharmaceuticals LLC, H1 2018

Hospital Acquired Pneumonia (HAP) Pipeline by AstraZeneca Plc, H1 2018

Hospital Acquired Pneumonia (HAP) Pipeline by Cardeas Pharma Corp, H1 2018

Hospital Acquired Pneumonia (HAP) Pipeline by Centauri Therapeutics Ltd, H1 2018

Hospital Acquired Pneumonia (HAP) Pipeline by CytaCoat AB, H1 2018

Hospital Acquired Pneumonia (HAP) Pipeline by Destiny Pharma Ltd, H1 2018

Hospital Acquired Pneumonia (HAP) Pipeline by Dong-A Socio Holdings Co Ltd, H1 2018

Hospital Acquired Pneumonia (HAP) Pipeline by Lakewood-Amedex Inc, H1 2018

Hospital Acquired Pneumonia (HAP) Pipeline by MedImmune LLC, H1 2018

Hospital Acquired Pneumonia (HAP) Pipeline by Meiji Seika Pharma Co Ltd, H1 2018

Hospital Acquired Pneumonia (HAP) Pipeline by Melinta Therapeutics Inc, H1 2018

Hospital Acquired Pneumonia (HAP) Pipeline by Merck & Co Inc, H1 2018

Hospital Acquired Pneumonia (HAP) Pipeline by Motif Bio Plc, H1 2018

Hospital Acquired Pneumonia (HAP) Pipeline by Nabriva Therapeutics plc, H1 2018

Hospital Acquired Pneumonia (HAP) Pipeline by Polyphor Ltd, H1 2018

Hospital Acquired Pneumonia (HAP) Pipeline by Sealife PHARMA GMBH, H1 2018

Hospital Acquired Pneumonia (HAP) Pipeline by Shionogi & Co Ltd, H1 2018

Hospital Acquired Pneumonia (HAP) Pipeline by Tetraphase Pharmaceuticals Inc, H1 2018

Hospital Acquired Pneumonia (HAP) Pipeline by Theravance Biopharma Inc, H1 2018

Hospital Acquired Pneumonia (HAP) Pipeline by Wockhardt Ltd, H1 2018

Hospital Acquired Pneumonia (HAP) Pipeline by Zavante Therapeutics Inc, H1 2018

Hospital Acquired Pneumonia (HAP) Dormant Projects, H1 2018

Hospital Acquired Pneumonia (HAP) Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports